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Abstract
Background—The Occluded Artery Trial (OAT) was a 2,201-patient randomized clinical trial
comparing routine stent-based percutaneous coronary intervention (PCI) versus optimal medical
therapy alone in stable myocardial infarction (MI) survivors with persistent infarct-related artery
occlusion identified day 3 to 28 post MI. Intent-to-treat analysis showed no difference between
strategies with respect to the incidence of new class IV congestive heart failure, MI, or death. The
influence of PCI failure, procedural hazard, and crossover on trial results has not been reported.
Methods—Study angiograms were analyzed and adjudicated centrally. Factors associated with PCI
failure were examined. Time-to-event analysis using the OAT primary outcome was performed by
PCI success status. Landmark analysis (up to and beyond 30 days) partitioned early hazard versus
late outcome according to treatment received.
Results—Percutaneous coronary intervention was adjudicated successful in >87%. Percutaneous
coronary intervention failure rates were similar in US and non-US sites, and did not significantly
influence outcome at 60 months (hazard ratio for success vs fail 0.79, 99% CI 0.45–1.40, P = .29).
Partitioning of early procedural hazard revealed no late benefit for PCI (hazard ratio for PCI success
vs medical therapy alone 1.06, 99% CI 0.75–1.50, P = .66).
Conclusions—Percutaneous coronary intervention failure and complication rates in the OAT were
low. Neither PCI failure nor early procedural hazard substantively influenced the primary trial results.
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The Occluded Artery Trial (OAT), undertaken in 83 US and 134 non-US sites, showed no
reduction in death, myocardial infarction (MI), or class IV heart failure when stable patients
with persistent infarct artery occlusion underwent routine coronary recanalization using
percutaneous coronary intervention (PCI) with stenting.1
Occluded Artery Trial eligibility defined an anatomically complex cohort with persistent
coronary occlusion due to a combination of organizing thrombus, occlusive plaque disruption,
or localized dissection. These features present technical challenges for PCI operators and have
been associated with PCI failure and periprocedural complications.2 The altered integrity of
the downstream nonreperfused infarct zone may have been vulnerable to reperfusion injury.3
We report herein the adjudicated frequency and mechanisms of PCI failure and the nature and
frequency of PCI-related complications in protocol-specified and early crossover procedures.
Percutaneous coronary intervention results in US and non-US sites are compared, and the
potential for PCI failure or an early PCI hazard to have influenced overall trial results is
examined.
Methods
Funded by the National Heart, Lung, and Blood Institute, the OAT was an international,
multicenter clinical trial testing the late open artery hypothesis through random assignment to
early PCI-based coronary recanalization (PCI) or optimal medical therapy alone (MED).
Supplementary funding and in-kind support from several corporate sources accounted for 6%
of the study budget.1 The authors were solely responsible for the design and conduct of this
study, all analyses, the drafting and editing of the paper and its final contents.
The final cohort consisted of 2,201 patients (2,166 main trial between February 2000 and
December 2005 + 35 OAT-NUC substudy extension between January and June 2006) enrolled
at 217 sites in 25 countries. Study rationale, design, and primary results have been previously
published.1,4 Subjects were eligible if coronary angiography demonstrated persistent
occlusion (thrombolysis in myocardial infarction [TIMI] grade 0 or 1 flow) of the infarct-
related coronary artery calendar day 3 to 28 post MI. Patients were required to meet at least
one high-risk criterion: proximal infarct-related artery (IRA) occlusion or ejection fraction
<50%. Those with New York Heart Association class IV congestive heart failure, shock,
spontaneous or provokable severe ischemia, 3-vessel, or left main coronary artery disease
warranting bypass surgery (coronary artery bypass graft) were excluded. Participating PCI
operators were required to document a case load of ≥75 PCIs per year, cumulative experience
as principal operator of ≥500 interventions, and a major complication rate of ≤2% during the
preceding year. Candidate sites submitted cineangiograms of recent PCI procedures targeting
occluded target segments for review and certification.
Percutaneous coronary intervention procedure guidelines
Protocol-assigned PCI procedures were performed within 24 hours of study enrollment. When
necessary, operators were expected to use various coronary guidewires with greater tip stiffness
or lubricity. Although PCI technical success was defined centrally as <50% residual in-segment
stenosis, operators were instructed to optimize the final result through complete coverage of
the target occlusion and adjacent lesion shoulder (including dissection) with one or more locally
approved bare metal or drug-eluting stents, seeking <20% residual diameter stenosis and
normal flow. High-pressure stent deployment (≥14 bar) and glycoprotein 2b3a inhibitors
(administered after guidewire crossing) and treatment of all significant lesions (>50% diameter
stenosis) in other major segments of the target vessel were strongly encouraged.
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Angiographic analysis
Diagnostic and protocol-assigned PCI cineangiograms were sent for central analysis and
adjudication to the Cardiovascular Imaging Research Core Laboratory, University of British
Columbia (directed by G.B.J.M. and C.E.B.). Quantitative analysis addressed the qualifying
segment, proximal reference vessel diameter, antegrade and collateral flow grades, and target
lesion dimensions (in-segment and in-stent) before and after PCI. The target lesion included
the target occlusion and adjacent lesion shoulder >50% diameter stenosis. Target segments
included additional 5 mm length proximal and distal perilesional zones. For consistency before
and after recanalization, only proximal reference segments were used in calculations of percent
diameter.2,5 Qualitative analysis categorized assigned PCI procedures as successful,
unsuccessful, or not attempted. Success was defined per protocol as <50% residual target
segment stenosis with TIMI grade 2 or 3 flow. During central review, we also prospectively
identified cases we deemed to be technically successful when final post-PCI flow remained
less than TIMI-2 despite technical success in the target segment providing no epicardial cause
for poor flow was present. Percutaneous coronary intervention failures were categorized by
prespecified mechanisms including (i) failure to cross (most distal wire position proximal to a
reconstituted distal segment), (ii) failure to reenter true lumen (most distal wire position at or
beyond a reconstituted distal segment, but extraluminal), (iii) in-segment residual stenosis
>50% for any reason, (iv) impaired distal runoff (TIMI flow 0 or 1) due to angiographically
visible intraluminal thrombus or dissection, (v) other. More than one mechanism could apply.
Baseline characteristics associated with PCI failure were examined.
Site-specific rates of angiographic procedural success were monitored. When procedure
success fell <80% (after ≥5 protocol-assigned interventions) or when any procedural failure
occurred during a site's first 4 assigned interventions, a review process addressing case-specific
factors was initiated that engaged the site's investigators.
Complications and events
Complications were categorized as coronary perforation, proximal coronary dissection, or
embolism causing or threatening ischemia in a nontarget territory, cardiac rupture, cardiac
tamponade, major bleeding, vascular complication requiring surgical repair, ventricular
arrhythmias requiring immediate intervention, stroke, or other. All recognized complications
were counted, including multiple complications in a single patient. Complications were
adjudicated as related or unrelated to PCI by an independent Morbidity and Mortality
Classification Committee blinded to treatment assignment. Prespecified OAT end-point events
were death, MI, or class IV congestive heart failure.1,4
PCI complications within 48 hours of study enrollment were examined using both intention-
to-treat and treatment-received principles. Prespecified primary outcome events through 60
months of follow-up were analyzed by intention-to-treat, treatment-received, and PCI success
status. Treatment-received analyses were based on treatment received within the first 30 days
after randomization. The potential contribution of an early PCI hazard to overall trial results
was explored by landmark analysis partitioning early (≤30 days) and late events (>30 days
through 60 months) on an intention-to-treat basis.
Statistical methods
With the use of SAS version 9.1.3 (SAS Institute, Cary, NC), baseline characteristics were
summarized as frequencies and percentages for categorical variables and as means with SDs
or medians with interquartile ranges for continuous variables. Intergroup comparisons were
performed using χ2/Fisher exact test for categorical variables and Student t test or Wilcoxon
rank test for continuous variables. Multivariable logistic regression model was developed to
evaluate the relationship between baseline characteristics and successful PCI. Estimates of the
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cumulative event rates were calculated by the Kaplan-Meier product-limit method, and groups
were compared by the log-rank test of the 5-year curves.6 Hazard ratio and 99% CIs were
calculated by Cox proportional hazards regression models.7 The OAT protocol prespecified a
P value of .01 as the threshold for showing significant differences in all secondary analysis.
This work was supported by the National Heart, Lung, and Blood Institute (U01 HL062509,
U01 HL062511). The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Heart, Lung, and Blood Institute or the National
Institutes of Health. Supplemental grant funds and product donations equivalent to 6% of total
study cost were received from Eli Lilly, Millennium Pharmaceuticals, Schering Plough,
Guidant, Cordis, Johnson & Johnson, Medtronic, Merck, and Bristol Myers Squibb Medical
Imaging.
Results
Angiographic characteristics, PCI variables, and quantitative angiographic analyses are
presented in Table I through Table III. Angiography was analyzed and adjudicated centrally
in 2,183 (99.2%) of 2,201 patients enrolled. Percutaneous coronary intervention was attempted
within 30 days of enrollment in 1,090 (99%) of 1,101 patients assigned PCI and in 33 (3%) of
1,100 patients assigned MED (Table II). Among PCI-assigned patients, stents were used in
86.1% and glycoprotein inhibitors in 66.7%. Procedures were deemed successful per protocol
in 879 cases and technically successful in 65 additional cases. Combining these, we observed
PCI success of 944 (87.3%) of 1,081 centrally adjudicated cases and in 953 (87.4%) of 1,090
attempts overall. Success rates and the use of stents and glycoprotein IIb/IIIa inhibitors were
similar across coronary territories.
Mechanisms of PCI failure were adjudicated in 135 (99%) of 137 cases. Failure to fully cross
the occluded segment with a guidewire was most common (n = 77, 57%), followed by failure
to reenter true lumen (n = 34, 25%), residual stenosis >50% (n = 27, 20%), and extensive
thrombus (n = 13, 10%). Percutaneous coronary intervention success rates were similar in US
versus non-US sites (86.2% vs 86.7%, P = not significant). The incidence of prespecified
procedural complications including early death or MI (<48 hours from enrollment) was low
(Table IV). Core laboratory monitoring of adjudicated PCI success triggered protocol-specified
review of PCI practices in 10 sites. Nine additional sites were reviewed after unexpected PCI
failure observed in ≥1 individual cases. None required second review or termination.
Preprocedural characteristics of PCI-assigned patients are compared according to PCI success
or failure in Table V. Of 50 characteristics examined, those independently predictive of failure
were prior PCI (P < .001) and TIMI grade 0 (P = .007) with trends noted for Killip class ≥2
(P = .013) and male sex (P = .04).
Sixty-month estimates of death, MI, class IV HF, and their composite were similar when PCI-
assigned subjects with successful PCI (per protocol or technical) were compared to those with
PCI failure. This finding was not materially influenced by exclusion of those with technical
success only. The as-treated analysis restricted to those PCI-assigned subjects with adjudicated
PCI success versus MED-assigned subjects without crossover PCI within 30 days showed no
difference in long-term outcomes either (Table VI, Figure 1). Finally, the landmark analysis
examining the primary composite end point before and after 30 days showed statistically
similar outcomes through 30 days (hazard ratio PCI/MED 1.4, 99% CI 0.8–2.4, P = .13). No
difference in late outcome by intention-to-treat was seen among those surviving beyond 30
days (Figure 2).
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Discussion
By resolving a longstanding controversy surrounding optimal care of MI survivors, publication
of primary results from the OAT has influenced recent guidelines for management of MI.8 The
results of any single strategic trial testing the incremental value of medical or surgical
procedures may be sensitive to the safety and efficacy with which the procedure in question
has been delivered.9 A thorough understanding of procedural outcomes and complications
experienced in the procedural arm becomes especially relevant when weighing the external
validity of these trials. Our report details the PCI procedural efficacy and remarkable safety
across a wide range of countries within the OAT to provide this context.
The OAT incorporated design features intended to ensure objective measures of procedural
outcomes. Principally, and despite the absence of angiographic end points per se, the trial used
an expert core angiographic laboratory charged with reviewing all protocol-driven coronary
angiographic images, including those recorded during protocol-assigned PCI procedures.
Beyond conventional quantitative and qualitative measurements, this allowed independent
adjudication of patient eligibility and, importantly, of PCI success. Furthermore, core review
of PCIs allowed objective, standardized categorization of PCI failure modes as well as
angiographically apparent complications such as perforation. Protocol adherence was excellent
with >99% of all assigned PCI procedures, including 98.5% of failed PCI procedures so
reviewed.
The OAT is by far the largest randomized interventional trial specifically examining PCI of
nonacute coronary occlusions. It captured the practices of numerous selected operators from
selected centers in 25 countries on 5 continents. We observed procedural success in 87.3% of
attempted adjudicated procedures and in 81.4% of patients with core laboratory–determined
TIMI flow 0 at baseline. Percutaneous coronary intervention success rates among 854 subjects
assigned PCI at a non-US center were nearly identical to those 247 subjects assigned PCI at a
major US center.
Our observed success rate is comparable to reports using routine stenting in similar populations.
Yousef et al10 reported PCI success in 30 (94%) of 32 patients assigned PCI for persistent left
anterior descending IRA occlusion in The Open Artery Trial at 2 major British centers. The
Open Artery Trial performed PCI 26 ± 17 days post MI, used a similar definition for PCI
success, but required single-vessel coronary disease and did not use an independent core
laboratory. The DECOPI trial performed at 16 centers in France and Belgium assigned 109
patients with persistent IRA occlusion to PCI performed a median of 8 days (interquartile range
5–11) after MI symptom onset.11 Protocol-defined success required restoration of TIMI-3 flow
and was reported in 82.2%, with TIMI-2 flow reported in an additional 4.7% (total 86.9%). In
contrast, a survey of reports describing PCI in chronic coronary occlusions (age >12 weeks)
found failure rates of 55% to 80%.12
The PCI failure modes we most commonly observed were incomplete coronary guidewire
passage (failure to cross) and failure to reenter the true lumen distal to the occlusion (subintimal
wire position). Although the incidence of failure is greater when treating chronic occlusions,
Kinoshita et al13 reported a similar distribution of failure modes in these patients (failure to
cross 64%; subintimal wire position 24%). These shared modes of procedural failure reflect
the limited precision in guidewire navigation inherent to current imaging. The association we
and others have observed between TIMI-1 (as opposed to TIMI-0) baseline flow and PCI
success is likely a consequence of the navigational clues provided by trace residual flow
through microchannels. Improvements in guidewire navigation may therefore improve
procedural results in subacute and chronic occlusions alike.
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We observed several associations with PCI success/failure that were unexpected and may be
due to chance. The apparent associations with low ejection fraction and prior PCI might be
explained by covariance with unmeasured characteristics of advanced and complex coronary
disease. The association with male sex is perplexing given the generally larger coronary arteries
in men and is likely due to chance. Notable was the lack of observed association between PCI
failure and presumed age of occlusion, whether expressed as median time from MI or as the
proportion of patients undergoing PCI beyond 7 days from index MI. Presumably, healing that
occurs during the first 4 weeks after initial occlusion precedes the development of dense fibrosis
or calcification that accounts for higher PCI failure rates in truly chronic occlusions.
Failure of the OAT to demonstrate benefit attributable to a strategy of PCI ran counter to much
previous experimental and observational data.14 On one hand, negative OAT results may
disprove the heretofore broadly accepted hypothesis that late infarct-artery patency is causally
related to improved outcomes. Alternatively, the meaning of the OAT results may be
biologically narrower, if no less clinically important. For instance, benefits attributable to late
patency might have been offset by limitations of contemporary PCI. Percutaneous coronary
intervention limitations apparent from the current analysis are several and include a significant
primary failure rate plus a procedural hazard that included a small excess incidence of major
complications and procedure-induced myonecrosis. To examine the potential influence of PCI
failure, we compared long-term outcomes of those with successful versus unsuccessful
protocol-assigned PCI (Figure 1, Table V). Although a weak trend favoring successful PCI
was observed, there was no suggestion of benefit for the cohort with successful PCI compared
to patients managed with medical therapy only. We note that a frequently cited report
comparing long-term outcomes after PCI success versus failure in nonacute and chronic
coronary occlusions did not include a medically treated control arm.15 To examine the potential
influence of early hazard, we performed a landmark analysis examining the primary end point
before and after 30 days (Figure 2). There appears to be a nonsignificant excess of adverse
events in the PCI arm up to 30 days. However, among those surviving beyond day 30, no
suggestion of late benefit attributable to PCI, and by extension to late IRA patency, is seen.
The absence of any signal for PCI benefit in these post hoc analyses suggests that persistent
or recurrent IRA occlusion is merely a marker of another more fundamental characteristic that
determines prognosis.
Limitations
Our analyses are primarily descriptive. Because of the small number of PCI failures (n = 137),
there is limited statistical power to examine factors associated with failure or measure the effect
of failure on outcome. The selection process for sites participating in the OAT was intended
to enrich the study with expert center and operators. Percutaneous coronary intervention
success rates achieved in less expert sites may be lower. Percutaneous coronary intervention
complications may not be apparent on angiographic images; thus our estimate of rates is
substantially dependent upon operator identification and voluntary site reporting of
complications. Specific case report forms were used for this purpose.
Conclusions
Our report describes in detail the high rates of PCI success and low rates of PCI complications
observed in the PCI arm of the OAT. Mechanisms of PCI failure in these subacute occlusions
resemble those in chronic occlusions. Analysis of long-term outcomes comparing cohorts with
PCI success versus failure and cohorts with PCI success versus MED (as-treated) does not
suggest that higher rates of PCI success or protocol compliance would have altered the findings
of the primary intention-to-treat analysis. Finally, we found no signal of late benefit attributable
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to routine PCI for persistent IRA occlusion in a landmark analysis designed to discount the
potential influence of procedural hazard.
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Figure 1.
Primary OAT outcome according to PCI success or failure (fail) in PCI-assigned patients, and
for reference, in MED-assigned patients treated without crossover to PCI or coronary artery
bypass graft within 30 days of enrollment (MED); no significant difference in outcomes over
5 years was detected (HR succ vs fail 0.79, 99% CI 0.45–1.40, P = .29; HR succ vs MED 1.11
99% CI 0.81–1.51, P = .40).
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Figure 2.
Landmark analysis of the OAT primary outcome by intention-to-treat (A) from enrollment
through 30 days and (B) after 30 days to 5 years.
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Table III
Distribution of angiography data by PCI success status (PCI arm)
Angiographic
variable
PCI Success
(n = 953)
PCI Fail
(n = 137)
No attempt
(n = 11) P
Baseline
  TIMI Flow n = 943 .02
    Grade 0 768 (81.4%) 125 (91.2%) 9 (81.8%)
    Grade 1 169 (17.9%) 12 (8.8%) 1 (9.1%)
    Grade 2 5 (0.5%) 0 (0.0%) 0 (0.0%)
    Grade 3 1 (0.1%) 0 (0.0%) 1 (9.1%)
MLD (mm)* 944, 0.0, 0.1 137, 0.0, 0.0 11, 0.1, 0.4 .02
% Diameter
     stenosis*
944, 99.8,
2.1
137, 100.0,
0.0
11, 96.0,
13.3
.01
Collaterals n = 939 .19
    Grade 0 120 (12.8%) 11 (8.0%) 3 (27.3%)
    Grade 1 671 (71.5%) 99 (72.3%) 8 (72.7%)
    Grade 2 148 (15.8%) 27 (19.7%) 0 (0.0%)
Post-PCI
  TIMI Flow n = 944
    Grade 0 2 (0.2%) N/A N/A
    Grade 1 9 (1.0%) N/A N/A
    Grade 2 54 (5.7%) N/A N/A
    Grade 3 879 (93.1%) N/A N/A
In-lesion*
  MLD (mm) 933, 2.2, 0.5 N/A N/A
  % Diameter
     stenosis
941, 29.3,
14.3
N/A N/A
In-stent*
  MLD (mm) 906, 2.7, 0.5 N/A N/A
  % Diameter
     stenosis
914, 14.0,
13.8
N/A N/A
Multivessel
     disease
156/945 =
16.5
29/137 =
21.2
4/11 =
36.4
.18
MLD, Minimum lumen diameter.
*
Values are shown as n, mean, SD.
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Table IV
Early complications and adverse events according to treatment assignment and treatment received
Treatment
assigned (ITT)
Treatment
received
Complication
PCI
(n = 1101)
MED
(n = 1100)
PCI
(n = 1123)
No PCI
(n = 1078)
Vascular 5 (4) 1 (0) 5 (4) 1 (0)
Major
    hemorrhage
8 (3) 1 (0) 9 (3) 0 (0)
CNS 3 (1) 2 (0) 2 (1) 3 (0)
Ventricular
    arrhythmia
6 (1) 2 (0) 6 (1) 2 (0)
Coronary
    perforation
4 (4) 1 (1) 5 (5) 0 (0)
Cardiac rupture 2 (1) 2 (0) 2 (1) 2 (0)
Nonfatal
    MI ≤48 h
8 (6) 2 (0) 10 (6) 0 (0)
Death <48 h 4 (3) 4 (1)* 4 (3) 4 (1)*
Elevated serum
    markers†
101/1031 30/933 104/1052 27/912
Values in parentheses indicate the number of complications adjudicated as PCI-related by Morbidity and Mortality Classification Committee.
ITT, Intent-to-treat; CNS, central nervous system.
*
Non-IRA PCI.
†
Site reported; marker elevation alone did not meet protocol prespecified criteria for MI.
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Table V
Distribution of baseline characteristics by PCI success status (PCI arm)
PCI Success
(n = 953)
PCI Fail (n
= 137)
No attempt
(n = 11) P*
Age, mean (SD) 58.5 (11.0) 58.8 (9.9) 62.8 (13.7) .74
Male 735 (77.1) 117 (85.4) 7 (63.6) .03
Days from MI,
    median (IQR)
8 (5–16) 9 (5–18) 6 (4–10) .27
Days 7–28 post MI 525 (55.1) 79 (57.7) 5 (45.5) .57
ST Elevation/new
    Q/R loss
829 (87.0) 118 (86.1) 10 (90.9) .78
Post fibrinolysis 192 (20.1) 31/136
(22.8)
4 (36.4) .47
Killip class ≥2 179/950
(18.8)
39 (28.5) 4 (36.4) .009
Diabetes 179 (18.8) 22 (16.1) 2 (18.2) .44
Current smoker 370 (38.8) 53 (38.7) 5 (45.5) .98
GFR (mL/min),
    mean (SD)
81.1 (21.4)
n = 937
78.8 (20.3)
n = 136
68.6 (21.1) .24
History of CHF 23 (2.4) 4 (2.9) 0 (0.0) .72
History of PCI 33 (3.5) 16 (11.7) 2 (18.2) <.001
EF, mean (SD) n = 946 47.8
(11.2)
45.7 (11.8) 42.4 (10.7) .04
LAD Target 341 (35.8) 36 (26.3) 6 (54.5) .03
TIMI 0 flow 768/943
(81.4)
125 (91.2) 9 (81.8) .005
Reference diameter
    (mm), mean (SD)
n = 832, 3.1
(0.7)
n = 114,
3.3 (0.9)
n = 7, 3.1
(0.4)
.06
Collateral present 819/939
(87.2)
126 (92.0) 8 (72.7) .12
Values are shown as n (%), unless otherwise specified.
GFR, Glomerular filtration rate; CHF, congestive heart failure; EF, ejection fraction.
*
Comparison (univariable) of PCI success vs PCI failure.
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